Its already starting this year. Go pick another technology that is not commercial to use that argument on. HYGS will likely be at a new post reverse split high sometime within a year,
Lets hope Ebola does not hit hard at home but it is a wake up call. All hospitals need to have the resources available just in case isolation occurs. Wallets should open up once again and revenues should turn up substantially in the coming quarters. It might not be the the next one since the US scare had yet to occur for the most of it.
AHPI gets a large portion of the respirator revenue worldwide. Every time an Ebola patient is moved respirators are necessary in the US. I am assuming the US will support using the same procedure in West Africa as the disease is combated there. Many people will be moved as new fever centers are built. There are many avenues AHPI will increase revenues as we attack Ebola back. Lets hope nobody on that flight Monday contracts Ebola or all hell will break loose in the US as those travelers went nationwide.
We already passed that point with VICL and their Ebola vaccine. Serepta is adding about Vical's entire market cap to theirs on that news. What happens when Vical reopens their study? It is necessary that government resources are thrown at all companies working or have worked on a vaccine.
Don't buy VICL for Ebola. Buy it for the ability to target any virus and its ability to help manufacture a vaccine of another company when proven successful. The study was halted when there were limited Ebola patients to treat.
Who knows how bad Ebola will get and what is coming at us next. Funding will be coming and those holding through the news could get a multibagger out of little Vical.
Vaccine Stocks should have a good run since we are seeing how much need is out there. Vical is a super buy here.
Dengue Fever is spreading much quicker this year than ever an Vical is working on a vaccine. Don't be surprised if the NHI reinstates their Vical Ebola Vaccine and helps cover the bill. Ebola starts in poor third world countries and anyone working on a vaccine was in it for the goodness of their heart. There has been a change of heart due to necessity and why start from scratch when Phase 1 was complete with Vical. Expect an announcement any time. We need as many tools as possible to battle Ebola.
type in infrared thermometer and find how many companies sell them for around thirty bucks. Almost a hundred is not a big deal
sold 100 to target ebola. Are they 50 bucks each... so like 5000 buck of revenue towards bola for a company facing trouble paying creditors a million bucks?
A vote of no could have dire consequences. If you have not known NVTL is cash flow negative and needs more time with the comeback. HC2 got a great deal out of this but that is OK as long as they give long term support and don't just start selling on any profit. If the overall deal falls through and Novatel Wireless has to give back the cash it could end up in a GTAT situation. Think before you just jump to a vote of no. It might be more difficult to get back to 5 bucks and higher per share but it decreases the chance of ending up with pennies or less. Think about it... The company and execs know more why the money is needed and the recent buys are signs of support that are not necessary with all the options granted in the first place. Yes it is a bad deal for shareholders but that is what Wall Street accepts (though inevitably will be the downfall of the market as a whole without changes and more regulation).
I traded GTAT as recent as a few weeks ago and over half of my money was tied to that. The day before the GTAT announcement 75% of my money was in NVTL but luckily none in GTAT. This reminded me of a hard lesson I luckily did not have to deal with first hand. 25% in on thing at the most unless it is a quick day trade on great news. Sorry I may have been part of the recent downtrend in the stock price but may go a bit stronger once the company cash position is more secure..
I personally decided to lower all of my holdings in equity until this Ebola deal is contained. I believe but hope I am wrong that little pockets will continue to appear in the states which would lead to a shutdown of international travel at least based on origination of travel. A small travel ban if stopped early but a much bigger one as we wait longer on an initial travel ban hoping luck is on our side. Ebola could take the world into recession if people begin avoiding public places. We will contain this catastrophe but not likely without a bit more pain first.
From 37 to 2000 districts. That is a substantial difference that should make a difference in the share price by the end of the day.
This is huge news that would be government supported. Great win for Novatel Wireless and Kajeet. I'd say this is in the likes of getting MiFi devices in connected cars.
This would really expand the orders for NVTL. Lets say 50 schools per district with probably 10 ordered per school would amount to 1 million MiFi devices. With repeat orders to keep the MiFi devices within the times.
Anyone know if there is any chance shareholders would not approve the merger. I would assume that under todays Ebola crisis this stock would leapfrog into the mid single digit dollar range if the merger falls through.
Vical Technology can be used to bring a vaccine to market very quickly. It may be theirs or it may not be but Vical has much more value today and the NIH will use the company once something acceptable is developed. Vical is contracted out to produce vaccines from the flu to Ebola. Sit and wait because one day you will wake up substantially richer one the news is out. This will likely be before stage three as the government will purchase vaccines to hit Ebola hard abroad before it gets out of hand here.
Vical Shares Spike Higher; Note Being Passed Around Indicating VICL, NIH Developing Needle-Free DNA Vaccine for Some Ebola Strains
Charles Gross, Benzinga Staff Writer October 01, 2014 2:24 PM
Look for it and you will see this. It is only a matter of time before VICL and its role in Ebola is brought to Wal Streets Attention.
HSV, HIV, Ebola, WNV, SARS, pandemic flu
$25+ million contract manufacturing
$20+ million additional grant funding